Marielle Fournel

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Sylvain Lefebvre, Daniel Delorme, A. Kalita, 2008, Molecular Cancer Therapeutics.

Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.

Daniel Delorme, O. Moradei, S. Leit, 2002, Journal of medicinal chemistry.

Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.

Daniel Delorme, A. Kalita, M. Robert, 2003, Journal of medicinal chemistry.

Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.

Alain Ajamian, Sylvain Lefebvre, Alina Nicolescu, 2009, Bioorganic & medicinal chemistry letters.

Sulfamides as novel histone deacetylase inhibitors.

Alain Ajamian, Sylvain Lefebvre, Alina Nicolescu, 2009, Bioorganic & medicinal chemistry letters.